StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.3
Power Rank trend -> Rising
06/13/2025 16:12:00 EST
Alnylam Pharmaceuticals Inc (ALNY)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, ALNY has been trading in a range between $308.00 and $285.31 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
ALNY is trading below resistance at $308.00, about 0% to the upside. There is support at $274.06 -11% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Alnylam Pharmaceuticals Inc $ALNY entered a Green zone 33 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $320.6216, a potential upside of 4.1% from the recent price of 307.99. The stock is trading 0.72% (potential upside) below its 52 week high of $310.22 and 102.23 % (potential downside) above its 52 week low of $152.30 - based on the recent price.
Company Summary
Alnylam Pharmaceuticals, Inc discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia.
News
| Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM. Source: Zacks Investment Research Tue, 10 Jun 2025 10:11:09 -0400 Sentiment: Positive |
| Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and onl. Source: Business Wire Mon, 09 Jun 2025 06:00:00 -0400 Sentiment: Neutral |
| Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the even. Source: Business Wire Wed, 28 May 2025 08:00:00 -0400 Sentiment: Neutral |
| 3 High-Flying Stocks That Could Soar Even More Many investors love the "big mo." That's short for "big momentum. Source: The Motley Fool Sat, 24 May 2025 06:40:00 -0400 Sentiment: Positive |
| Alnylam Issues 2024 Corporate Responsibility Report CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This year's edition highlights the company's progress, data, and stories demonstrating its commitment to patient access,. Source: Business Wire Tue, 20 May 2025 09:00:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 310.22 52 Week Low: 152.3 Beta: 0.211 50 Day MA: 269.331 200 Day MA: 263.3145 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.202 Forward PE: 10000 Trailing PE: 0